


Fluorescence to highlight the urethra: a human cadaveric study

T. G. Barnes^{1,2}  · M. Penna¹ · R. Hompes¹ · C. Cunningham¹

Received: 30 January 2017 / Accepted: 26 February 2017
© The Author(s) 2017. This article is an open access publication

Abstract

Background Urethral injury is a complication feared by surgeons performing transanal TME (TaTME) or abdominoperineal excision (APE) procedures. Injury during TaTME occurs when the prostate is inadvertently mobilised or as a direct injury similar to the direct injury during the perineal dissection of APE procedures. We performed a proof of principle study to assess the feasibility of using indocyanine green (ICG) to fluoresce the urethra in human cadavers.

Methods Indocyanine green at varying doses was mixed with Instillagel and infiltrated into the urethra of male human cadavers. The urethra was exposed through either a perineal incision or by mobilisation of the prostate during a TaTME dissection and fluorescence observed using a PINPOINT laparoscope (NOVADAQ). Brightness was assessed on the images using ImageJ (National Institute of Health).

Results Eight cadavers were included in the study. Fluorescence was visualised in the urethra in all eight cadavers. Minimal dissection was required to obtain fluorescence transperineally. In one cadaver, the urethra was demonstrated under fluorescence using a simulated TaTME with

additional fluorescence also being observed in the prostate. There was no correlation between brightness and dosing. **Conclusions** This novel proof of principle study demonstrates a simple way in which the urethra may be easily identified preventing it from injury during surgery.

Keywords Colorectal surgery · Laparoscopic surgery · Fluorescence · Urethral injury · Urethra · Rectal cancer

Introduction

Operative management of rectal cancer involves anterior resection in the form of a total mesorectal excision (TME) or, for low rectal cancers invading the sphincter muscles, abdominoperineal excision (APE) of the rectum is appropriate. Fifty-five per cent of patients diagnosed with rectal cancer undergo surgical resection, amounting to 5000 patients per year with 35% of these patients having neoadjuvant radiotherapy [1].

A recently developed procedure for TME dissection is to perform the procedure via a combined laparoscopic abdominal and endoscopic approach: transanal total mesorectal excision (TaTME). One major concern that has arisen regarding TaTME procedures is the risk of urethral injury [2, 3]. As many as 24 documented urethral injuries have occurred during the clinical adoption of this new technique (personal communication, Professor Patricia Sylla MD, Mount Sinai Hospital, New York). The injury occurs following inadvertent mobilisation of the prostate, putting the membranous urethra at risk [4]. This injury may be avoided with adequate training and mentoring in the technique. However, direct injury can still occur without prostate mobilisation during perineal dissection in an intersphincteric approach or APE.

Electronic supplementary material The online version of this article (doi:10.1007/s10151-017-1615-y) contains supplementary material, which is available to authorized users.

✉ T. G. Barnes
tom.barnes@doctors.org.uk

¹ Department of Colorectal Surgery, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

² Nuffield Department of Surgery, John Radcliffe Hospital, Headley Way, Headington OX3 9DS, UK

Dissection in the plane anterior to the anus is an area of concern even for experienced cancer surgeons, aggravated by unfavourable anatomy and the presence of an anterior rectal cancer. Increasing use of video-directed rectal cancer surgery [5] means that it is not often possible to palpate the urethral catheter during perineal dissection; therefore, enhanced reality imaging may be of value in defining the anatomy. The incidence of urethral injury during colorectal surgery is around 3% [6] and is more commonly seen in patients who have had neoadjuvant radiotherapy. The post-operative sequelae are a source of significant morbidity and frustration for the patient [7].

This study was a proof of principle study investigating the use of indocyanine green (ICG) as a fluorophore to help identify the urethra during all types of perineal dissection where the urethra may be difficult to visualise.

Materials and methods

Eight freshly frozen male cadavers were obtained through the Department of Anatomy, University of Oxford, and the study was ethically approved internally by the same department. All cadavers had been used for a TaTME training course earlier the same day. Cadavers were placed in a modified Lloyd Davies position and where possible, a 14fr Foley catheter was placed in the urethra with 10 ml of saline used to inflate the balloon.

ICG (Verdye, Diagnostic Green, Aschheim-Dornach, Germany) was reconstituted using normal saline and mixed with 10 ml of Instillagel (CliniMed, Loudwater, High Wycombe, Bucks, UK). Ten millilitres of ICG was infiltrated directly into the lumen of the urethra whilst the urethra was manually occluded. Where a urinary catheter was in place, ICG was infiltrated adjacent to the catheter into the urethra. Dosing of ICG was as follows: 2.5, 5, 10, 12.5 and 25 mg. Dissection was performed down to the urethral wall with observation of fluorescence signal using the PINPOINT laparoscopic system (NOVADAQ, Bonita Springs, FL, USA). The PINPOINT system emits a laser at 806 nm and filters the fluorescence signal at 835 nm.

The urethra was then exposed through the perineum using either a transverse or vertical incision. In cadavers where the prostate had been intentionally mobilised as part of the learning process during the TaTME procedure, the anastomosis was taken down, the abdomen closed and the urethra visualised through the transanal platform.

Brightness values were calculated using ImageJ (version 2.0.0) [8]. A freehand selection was drawn around the urethra in white light mode and applied to the images obtained under fluorescence and brightness measure (the software calculates brightness values by calculating the mean of red, green and blue pixels). Data were analysed

using Prism (V7.0a, Graphpad) and SPSS statistics (version 22.0, IBM corp). Where there was more than one cadaver for a dosing cohort, the means and standard deviations were combined using a standard formula [9]. The relationship between dosing and brightness was calculated using linear regression.

Results

All cadavers displayed fluorescence in the urethra after infiltration of ICG/Instillagel mixture. A perineal incision was utilised in seven cadavers. Of these, five had a urinary catheter in situ and we subjectively observed similar levels of fluorescence to those in cadavers without a urinary catheter. To assess whether ICG could be infiltrated down a lumen of a Foley catheter rather than the urethra, we imaged a catheter using ICG to the fill balloon lumen. Using the PINPOINT laparoscope, no fluorescence was observed along the any part of the length of the catheter.

The PINPOINT system allows visualisation of pure fluorescent signal as a black and white image (SPY mode) and an overlay of fluorescence (green) on a white light image. Example images of urethral fluorescence are shown in Figs. 1 and 2.

It was not necessary to completely denude the urethra in any of the cadavers as fluorescence was seen through the overlying muscle. After exposing the urethra and observing fluorescence, we deliberately breached the urethral wall and observed leakage of ICG and Instillagel. As expected, the leaking material did not fluoresce but was green under white light (Fig. 3).

In the cadavers, where it was not possible to insert a catheter, there was concern about ICG leaking into the bladder and the fluorescence being lost. The opposite occurred and ICG appeared to 'stain' the lining of the urethra (Fig. 4).

In one cadaver, the prostate had been inadvertently mobilised during the TaTME dissection. With the transanal platform in situ, ICG was infiltrated and fluorescence was observed clearly delineating the urethra. The prostate was further mobilised purposely, and signal was also detected in the prostate (Fig. 5).

Comparison of brightness between dosing cohorts revealed no relationship between dose and brightness (Pearson's correlation coefficient -0.297 , $p = 0.314$) (Fig. 6).

Discussion

This proof of principle study demonstrates that there is a potential use for fluorescence in identifying and protecting the urethra during colorectal surgery. This could be applied

Fig. 1 Fluorescence clearly seen in both SPY mode and the overlay. In the white light image (top left thumbnail), the urethra is not seen with white light alone





Fig. 2 Urethral dissection without entering the overlying muscle and fluorescence is still seen—SPY mode



to TaTME, intersphincteric dissections or APE procedures, where the urethra is particularly at risk.

In all eight cadavers, fluorescence signal was observed in the urethra after infiltration. The urethra was easily seen through a perineal incision and demonstrates that the ICG emission easily penetrates the overlying muscle to allow visualisation to a depth of 2–4 cm [10, 11]. ICG is known to have a low level of fluorescence in aqueous solution with its emission increasing when bound to

plasma proteins or cellular membranes [12]. This explains the observation that fluorescence was observed ‘sticking’ to the mucous membrane of the urethra and not observed in the leaked Instillagel. ICG is commonly used intravenously to assess perfusion and subcutaneously, submucosally or subserosally to assess lymphatics. There is no published literature surrounding its application directly onto mucous membranes [13] nor is it licensed for this purpose. Future work would require a feasibility study to




Fig. 3 On breaching the urethra, there is a leak of the Instillagel containing ICG. Whilst this appears green on a white light image, there is no true fluorescence (SPY mode) unless ICG is bound to the tissue




Fig. 4 After breaching the urethra, the ICG is seen to have stained the lining of the urethra

assess dosing, timing and safety for its use intraoperatively. It is likely to be a safe technique as we demonstrated that a low dose (2.5 mg) can be utilised with the likelihood of lower doses being efficacious. Infiltration of the catheter with ICG rather than the urethra does not produce detectable fluorescence.

This technique is likely to be of greatest benefit in APE procedures. This technology can potentially enhance TaTME, and reassurance would be provided where fluorescence is not visualised. Whilst one would not expect to see the urethra when in the correct plane during TaTME, the ability of urethral fluorescence to also highlight the




Fig. 5 Demonstration of urethral fluorescence during a simulated TaTME. *Orange line* urethral outline; *Blue outline* prostate




Fig. 6 Relationship of brightness against dose of ICG. *Dots* represent the mean or combined mean brightness for each dose and *error bars* standard deviation

prostate has been demonstrated here and may even help the surgeon to determine the correct plane during the anterior dissection.

Conclusions

This novel technique using fluorescence may help prevent urethral injury during perineal dissection. Studies are needed to establish its feasibility and safety in live patients.

Acknowledgements The authors would like to thank Mr. David James, Ms. Marta Penna, Mr. Tom Cosker, Matt McKittrick and the Department of Anatomy, Oxford University, for their contributions to this study. NOVADAQ provided the PINPOINT stack for the study on loan. No monetary support was provided for the study. Mr. Thomas Barnes was supported by a Research Fellowship from the Royal

College of Surgeons of England. Verdyne supplied the Indocyanine Green used for the study.

Compliance with ethical standards

Conflict of interest The authors declare that they have no conflict of interest. NOVADAQ supplied the PINPOINT equipment on loan for the purposes of this study. No direct financial benefit was incurred. Verdyne supplied the ICG for the purposes of this study. No direct financial benefit was incurred.

Ethical approval All procedures were performed were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments.

Informed consent Informed consent was obtained from all individual participants included in the study.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References

1. NHS Digital (2016) National bowel cancer audit report—2015. <http://content.digital.nhs.uk/searchcatalogue?productid=19790&q=title%3a%22bowel+cancer%22&sort=Relevance&size=10&page=1>
2. Simillis C, Hompes R, Penna M, Rasheed S, Tekkis PP (2016) A systematic review of transanal total mesorectal excision: Is this the future of rectal cancer surgery? *Colorectal Dis* 18:19–36
3. Penna M, Hompes R, Arnold S et al (2016) Transanal total mesorectal excision: international registry results of the first 720 cases. *Ann Surg*. doi:10.1097/SLA.0000000000001948

4. Atallah S, Albert M, Monson JR (2016) Critical concepts and important anatomic landmarks encountered during transanal total mesorectal excision (TaTME): toward the mastery of a new operation for rectal cancer surgery. *Tech Colooproctol* 20:483–494
5. Buchs NC, Kraus R, Mortensen NJ et al (2015) Endoscopically assisted extralevator abdominoperineal excision. *Colorectal Dis* 17:277–280
6. Eswara JR, Raup VT, Potretzke AM, Hunt SR, Brandes SB (2015) Outcomes of iatrogenic genitourinary injuries during colorectal surgery. *Urology* 86:1228–1233
7. Delacroix SE Jr, Winters JC (2010) Urinary tract injuries: recognition and management. *Clin Colon Rectal Surg* 23:104–112
8. Schneider CA, Rasband WS, Eliceiri KW (2012) NIH image to imageJ: 25 years of image analysis. *Nat Methods* 9:671–675
9. Higgins JPT, Green S (2016) Cochrane handbook for systematic reviews of interventions 2011. http://handbook.cochrane.org/chapter_7/7_7_3_data_extraction_for_continuous_outcomes.htm
10. Houston JP, Thompson AB, Gurfinkel M, Sevvick-Muraca EM (2003) Sensitivity and depth penetration of continuous wave versus frequency-domain photon migration near-infrared fluorescence contrast-enhanced imaging. *Photochem Photobiol* 77:420–430
11. Marshall MV, Rasmussen JC, Tan IC et al (2010) Near-infrared fluorescence imaging in humans with indocyanine green: a review and update. *Open Surg Oncol J* 2:12–25
12. Golijanin J, Amin A, Moshnikova A et al (2016) Targeted imaging of urothelium carcinoma in human bladders by an ICG phlip peptide ex vivo. *Proc Natl Acad Sci USA* 113(42):11829–11834
13. Boni L, David G, Mangano A et al (2015) Clinical applications of indocyanine green (ICG) enhanced fluorescence in laparoscopic surgery. *Surg Endosc* 29:2046–2055